Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

AstraZeneca loses second top executive as Vectura gets new CEO

June 24, 2015
Life sciences
(Reuters) – AstraZeneca has lost a second senior executive in a fortnight with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
 
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
 
An AstraZeneca spokeswoman said on Wednesday that the timing of the departures was “pure coincidence” and both men were moving on to new and different types of challenges as business leaders.
 
Vectura said Ward-Lilley would become CEO effective Oct. 1, replacing Chris Blackwell, whose departure had already been announced and who will leave the small drug company at the end of this month.
 
The move is a blow to AstraZeneca, which has identified respiratory medicine as one of its six growth businesses, alongside oncology, diabetes, the heart drug Brilinta, emerging markets and Japan.
 
AstraZeneca CEO Pascal Soriot, who took over in 2012 and successfully fought off a $118 billion takeover attempt by Pfizer last year, has sought to bolster the company’s respiratory franchise.
 
The drugmaker already boasts an established blockbuster in its inhaled treatment Symbicort, for asthma and chronic lung disease, and Soriot plans to build on that after buying Pearl Therapeutics in 2013 and Almirall’s lung drug business in 2014.
 
Vectura, whose shares traded 1 percent higher by mid-morning, said Trevor Phillips would act as interim CEO from the end of June until Ward-Lilley joined the company.
 
(Additional reporting by Roshni Menon in Bengaluru; Editing by Pravin Char)

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Read more
September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Read more
September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

Read more
More news

How can we help you?

We're easy to reach